Paclitaxel-carboplatin-gemcitabine (TCG) as first-line treatment of ovarian cancer: a prospective multicenter phase II study (AGO-OVAR 8) followed by a prospectively randomized phase III GCIG Intergroup study (AGO-OVAR 9, GINECO-TCG, NSGO-OC-0102) compari

Titel:: Paclitaxel-carboplatin-gemcitabine (TCG) as first-line treatment of ovarian cancer: a prospective multicenter phase II study (AGO-OVAR 8) followed by a prospectively randomized phase III GCIG Intergroup study (AGO-OVAR 9, GINECO-TCG, NSGO-OC-0102) compari
Dokumenttyp:: Article
Autor(en):: du Bois, A; Sehouli, J; Lund, B; Joly, E; Huober, J; Jensen, TS; Levy, E; Heilmann, V; Boman, K; Hardy-Bessard, AC; Burges, A; Maenpaa, J; Pujade-Lauraine, E; Pfisterer, J; Gropp, M; Staehle, A; Wimberger, P; Jackisch, C; Schmalfeldt, B; Belau, A; Loibl, S; Wollschlaeger, K; Canzler, U; Rochon, J
Zeitschriftentitel:: Int J Gynecol Cancer
Jahr:: 2005
Band / Volume:: 15 Suppl.
Seitenangaben Beitrag:: 224-225
Sprache:: eng
Print-ISSN:: 1048-891X
TUM Einrichtung:: Frauenklinik und Poliklinik
BibTeX

Vorkommen: